

Announcement no. 19/2008

NASDAQ OMX Nordic Exchange Copenhagen

Copenhagen, November 24, 2008

NOTICE
convening an Extraordinary General Meeting of Curalogic A/S
(CVR reg. no. 27 97 06 05)
on Thursday December 11, 2008 at 2.00 pm (CET)

The shareholders of Curalogic A/S, CVR no. 27970605, are summoned to an Extraordinary General Meeting to be held on Thursday December 11, 2008 at 2.00 pm (CET) at FUUH Conference Center, Fiolstræde 44, 1171 Copenhagen K, Denmark.

AGENDA

1. Proposal from the Board of Directors to dissolve Curalogic A/S by solvent winding-up

Since Curalogic A/S has not succeeded in re-establishing a satisfactory biotech pipeline the Board of Directors proposes to dissolve the company by solvent winding-up under Chapter 14 of the Danish Companies Act in order to assure that the liquid assets of the company are returned to the shareholders.

If the proposal is adopted by the general meeting, section 1.1 of the Company's Articles of Association will be amended to:

"The name of the Company is Curalogic A/S in liquidation"

and section 14.1 of the company's Articles of Association will be amended to:

"The Company shall be bound by legal obligations entered into on behalf of the Company by the liquidator"

2. Proposal from the Board of Directors to appoint a liquidator

The Board of Directors proposes that attorney-at-law Tomas Haagen Jensen from the law firm Gorrissen Federspiel Kierkegaard is appointed as liquidator.

---o0o---

The Company's share capital is nominally DKK 28,240,074,50, divided into shares of DKK 0.50 each or multiples thereof. Each nominal shareholding of DKK 0.50 carries one vote. Shareholders entitled to admission who have entered their names in the register of shareholders or have registered and documented the acquisition have the right to vote. Shareholders who have acquired their shares by way of transfer do not have the right to vote at the general meeting, unless the shares are in the register of shareholders or the shareholder has registered and documented the acquisition before the publication of the notice, cf. section 9.1 of the Articles of Association.

For adoption of the proposal regarding item 1 of the agenda at least two thirds of the votes cast as well as of the share capital represented at the general meeting must vote in favour of the proposal, cf. the Danish Companies Act. For adoption of the proposal regarding item 2 of the agenda, a simple majority must be in favour of the proposals, cf. section 10.1. of the Articles of Association.

---o0o---

No later than 8 days prior to the general meeting, the agenda and the complete proposals will be made available at the offices of Curalogic A/S. The complete proposals are also available at the website of Curalogic A/S www.curalogic.com under "Investor Relations".

It is a prerequisite for access to and the exercising of voting rights at the general meeting that the shareholder has received an admission card no later than 5 days prior to the general meeting. Shareholders who cannot attend the general meeting can exercise their rights by proxy to the Board of Directors or to a person appointed by the shareholder who attends the general meeting.

An authorisation form for voting is available at VP Investor Services A/S or Curalogic A/S. Any dividend and liquidation proceeds on shares are paid out via the Danish Securities Centre to the shareholders' accounts with the respective account holding institutions through which the financial rights are exercised, cf. the second sentence of section 73(5) of the Danish Companies Act.

The Board of Directors of Curalogic A/S

The Extraordinary General Meeting will be announced in the Danish newspaper Berlingske Tidende on Tuesday November 25, 2008.

For additional information, please contact:

Jakob Schmidt, Chairman	Tel. +45 20 22 68 60
Helle Busck Fensvig, EVP and CFO	Tel. +45 99 99 24 03

This announcement contains forward-looking statements regarding the Company's future financial development and performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of the Company's knowledge and belief, are reasonable, at this time, but may prove to be erroneous in the future.